55 related articles for article (PubMed ID: 6957264)
1. Modulation of cytarabine metabolism in the human promyelocytic leukemia cell line HL-60 by polyhydroxy-substituted benzohydroxamic acids.
Howell SB; Gill S; Elford HL
Cancer Treat Rep; 1982 Oct; 66(10):1825-9. PubMed ID: 6957264
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
3. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
Grant S; Turner AJ; Bartimole TM; Nelms PA; Joe VC; Jarvis WD
Oncol Res; 1994; 6(2):87-99. PubMed ID: 7949469
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity.
Rauscher F; Cadman E
Cancer Res; 1983 Jun; 43(6):2688-93. PubMed ID: 6189585
[TBL] [Abstract][Full Text] [Related]
5. Amidox, an inhibitor of ribonucleotide reductase, potentiates the action of Ara-C in HL-60 human promyelocytic leukemia cells.
Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Fritzer-Szekeres M; Szekeres T
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1541-4. PubMed ID: 15571294
[TBL] [Abstract][Full Text] [Related]
6. Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells.
Leclerc JM; Momparler RL
Cancer Treat Rep; 1984 Sep; 68(9):1143-8. PubMed ID: 6592037
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent enhancement of 1-beta-D-arabinofuranosylcytosine incorporation into HL-60 DNA by deoxyguanosine.
Ross DD; Akman SA; Joneckis CC; Yang E; Bachur NR
Cancer Res; 1984 Apr; 44(4):1530-5. PubMed ID: 6584206
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
Grant S; Bhalla K; Rauscher F; Cadman E
Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
[TBL] [Abstract][Full Text] [Related]
9. Deoxyguanosine enhancement of cytarabine nucleotide accumulation in human leukemia cells.
Akman SA; Ross DD; Joneckis CC; Fox BM; Bachur NR
Cancer Treat Rep; 1985; 69(7-8):851-7. PubMed ID: 4016794
[TBL] [Abstract][Full Text] [Related]
10. Metabolism, incorporation into DNA, and interactions with 1-beta-D-arabinofuranosylcytosine of 5-hydroxymethyl-2'-deoxyuridine in human promyelocytic leukemia cells (HL-60).
Vilpo JA; Vilpo LM
Cancer Res; 1988 Jun; 48(11):3117-22. PubMed ID: 3163271
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
12. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
[TBL] [Abstract][Full Text] [Related]
13. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
14. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells.
Bornhäuser M; Illmer T; Le Coutre P; Pursche J; von Bonin M; Freiberg-Richter J; Schaich M; Platzbecker U; Thiede C; Ottmann OG; Köhne Ch; Braess J; Ehninger G; Schleyer E
Ann Hematol; 2004; 83 Suppl 1():S61-4. PubMed ID: 15124675
[TBL] [Abstract][Full Text] [Related]
16. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
17. A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells.
Yamauchi T; Ueda T
Biochem Pharmacol; 2005 Jun; 69(12):1795-803. PubMed ID: 15935150
[TBL] [Abstract][Full Text] [Related]
18. Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
Höchtl T; Horvath Z; Bauer W; Karl D; Saiko P; Elford HL; Fritzer-Szekeres M; Szekeres T
Life Sci; 2004 Jan; 74(9):1071-80. PubMed ID: 14687648
[TBL] [Abstract][Full Text] [Related]
19. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells.
Bhalla K; Swerdlow P; Grant S
Blood; 1991 Dec; 78(11):2937-44. PubMed ID: 1954383
[TBL] [Abstract][Full Text] [Related]
20. Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells.
Walsh CT; Craig RW; Agarwal RP
Cancer Res; 1980 Sep; 40(9):3286-92. PubMed ID: 7427943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
